The Analgesic Effect of Methocarbamol: A Systematic Review
BioChem · 10.11.2026 · 6 (4) · 35
DOI: 10.3390/biochem6040035 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BioChem, online erschienen am 10.11.2026. Verfasst von Carolina Damas Pereira und 16 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Methocarbamol is a centrally acting skeletal muscle relaxant widely used for musculoskeletal pain associated with muscle spasm, despite an incompletely understood mechanism of action and uncertainty regarding its efficacy compared with placebo or other pharmacological interventions.
Objective
To evaluate the efficacy of methocarbamol in reducing pain intensity in adults (≥18 years) with acute or chronic pain, compared with placebo or other pharmacological interventions, and to assess its impact on quality of life and other pain-related outcomes.
Methods
This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261440769). PubMed, Scopus, Web of Science, and Cochrane Library were searched from inception to 30 May 2026. Randomized and non-randomized controlled trials, cohort studies, case series, and narrative or systematic reviews reporting an extractable pain-related outcome were eligible. Risk of bias was assessed using RoB 2, ROBINS-I, or the Newcastle–Ottawa Scale, and level of evidence was graded per OCEBM 2011 criteria. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively.
Results
Twenty-eight studies (1959–2025; n = 30–9089), comprising 9 randomized controlled trials, 14 observational studies, 4 narrative/bibliographic reviews, and 1 case series, were included, spanning acute low back pain, postoperative/perioperative pain, trauma (including rib fractures), trigeminal neuralgia, cirrhosis-related muscle cramps, muscle strain, and opiate withdrawal. Results were inconsistent across indications: some trials showed benefit when methocarbamol was combined with NSAIDs or compared with opioids, while others—including the largest cohorts—found no advantage, partly attributable to confounding by indication. Opioid-sparing effects were observed in select postoperative and trauma populations. Methodological quality was generally moderate-to-high risk of bias.
Conclusions
Evidence supporting methocarbamol’s analgesic efficacy is heterogeneous and inconclusive. Benefit appears most plausible in pain syndromes driven by muscle spasm, and it may have a role within multimodal, opioid-sparing strategies in selected postoperative and trauma settings. The available evidence is insufficient to support routine use across the clinical settings evaluated. Adequately powered, standardized randomized controlled trials are needed to clarify its true effect and identify patients most likely to benefit.
Zitieren
APA
Pereira, C. D., Silva, G., Sousa, B., Portela, C., Teixeira, C. V., Mendes, D., Araújo, M., Santos, M., Moutinho, P., Costa-Duarte, A., Rodrigues-Lopes, R., Severino, A., Oliveira, M., Guerra, I., Rocha-Neves, J., Martins, I., & Ribeiro, H. (2026). The Analgesic Effect of Methocarbamol: A Systematic Review. BioChem, 6(4), 35. https://doi.org/10.3390/biochem6040035
Vancouver
Pereira CD, Silva G, Sousa B, Portela C, Teixeira CV, Mendes D, et al. The Analgesic Effect of Methocarbamol: A Systematic Review. BioChem. 2026;6(4):35. doi:10.3390/biochem6040035
BibTeX
@article{Pereira2026,
author = {Pereira, Carolina Damas and Silva, Gonçalo and Sousa, Beatriz and Portela, Carolina and Teixeira, Carolina Vilela and Mendes, Duarte and Araújo, Marco and Santos, Mariana and Moutinho, Pedro and Costa-Duarte, Alexandra and Rodrigues-Lopes, Rita and Severino, Ana and Oliveira, Matilde and Guerra, Inês and Rocha-Neves, João and Martins, Ivis and Ribeiro, Hugo},
title = {The Analgesic Effect of Methocarbamol: A Systematic Review},
journal = {BioChem},
year = {2026},
volume = {6},
number = {4},
pages = {35},
doi = {10.3390/biochem6040035}
}
EUVIMED